Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2022-03-31 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
独立董事关于第四届董事会第三十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is a statement of independent directors providing their opinion on a specific board meeting matter related to the change of some fundraising special accounts. It references regulatory guidelines and company rules but does not contain financial statements or detailed financial data. The document length is short (479 characters), and it is an opinion related to board decisions rather than a full report or announcement of voting results. It fits best under Board/Management Information (MANG) as it concerns board-level decisions and opinions.
2022-03-31 Chinese
第四届董事会第三十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by the company 健帆生物科技集团股份有限公司. It details the convening of the fourth board's 32nd meeting, attendance, and the approval of a proposal regarding the change of some fundraising special accounts. It includes voting results and mentions that the independent directors and sponsoring institutions have given their opinions. The document is short (767 characters) and is an announcement of a board decision rather than a full report or financial statement. It does not contain financial data or detailed management discussion but focuses on board meeting resolutions. Therefore, it fits best under Board/Management Information (MANG).
2022-03-31 Chinese
关于变更部分募集资金专户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the change of some special accounts for raised funds. It details the approval by the board and supervisory committee, the regulatory compliance, and the transfer of funds between bank accounts. It does not contain financial statements or detailed financial results but is focused on the management and use of raised capital. The document length is about 3,033 characters, which is relatively short and reads like a formal announcement rather than a full financial report. The content is about fundraising account management and changes, which fits the category of Capital/Financing Update rather than a full Annual Report, Interim Report, or Audit Report. Therefore, the best classification is Capital/Financing Update (CAP).
2022-03-31 Chinese
中航证券有限公司关于公司变更部分募集资金专户的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from the sponsoring institution (中航证券有限公司) regarding the change of certain special accounts for raised funds by 健帆生物科技集团股份有限公司. It references regulatory guidelines related to the management and use of raised funds, details the amounts raised, the use of funds, and the approval process by the board, supervisory committee, and independent directors. The document is not a financial report itself but an official verification and opinion on the change of fundraising account management. It does not contain financial statements or earnings data but is a regulatory compliance and verification document related to capital management. Therefore, it fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters, but it contains substantive content about capital management changes, not just an announcement of a report publication or a certification letter, so it is not RPA or RNS. Hence, the classification is CAP with high confidence.
2022-03-31 Chinese
第四届监事会第三十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution by the company, detailing the meeting attendance, agenda, and voting results. It includes a statement ensuring the accuracy and completeness of the disclosed information. The content focuses on the approval of a proposal related to changing some fundraising accounts, with no financial statements or detailed financial data presented. The document is relatively short (689 characters) and serves as an official announcement of a board decision rather than a full report or detailed financial disclosure. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a voting result announcement for a shareholder meeting but a supervisory board meeting resolution. Given the nature of the content, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2022-03-31 Chinese
关于公司中空纤维血液透析器产品取得欧盟CE认证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the achievement of EU CE certification for a new product by a subsidiary. It details the certification specifics, product impact, and risk warnings. There is no financial data, no mention of a report being attached or published, and no regulatory form references. The content is an official announcement about a product certification and its business impact, which fits best under general regulatory announcements that do not fit other categories.
2022-03-30 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.